Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Treatment of severe hypoglycemia outside of the hospital setting is limited to glucagon formulations requiring reconstitution before use, which may lead to erroneous or delayed glucagon administration. We compared the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics and safety and tolerability of different doses of dasiglucagon, a novel soluble glucagon analog, with approved pediatric and full doses of GlucaGen in insulin-induced hypoglycemia in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion. RESULTS: Dasiglucagon demonstrated a dose-dependent and rapid increase in plasma concentrations, reaching a maximum at ∼35 min with a half-life of ∼0.5 h. Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9–14 min) to PG ≥70 mg/dL (within 6–10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG. All patients on both treatments reached these end points within 30 min (predefined success criteria). Both treatments were well tolerated. Nausea was the most frequent adverse event, occurring at a similar rate (44–56%). CONCLUSIONS: Dasiglucagon was well tolerated and showed an early PD response similar to that of GlucaGen at corresponding doses, suggesting comparable clinical effects of the two glucagon formulations. Dasiglucagon has the potential to become an effective and reliable rescue treatment for severe hypoglycemia in a ready-to-use pen.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These new FDAeapproved formulations have demonstrated glycemic responses similar to standard glucagon formulations for the treatment of hypoglycemia but without the need of reconstitution.1230”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1230]
Citations
Cites
(2) Classification and diagnosis of diabetes
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s005 · Cited by 1,841
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602
Wood, J. R., Miller, K. M., Maahs, D. M., Beck, R. W., DiMeglio, L. A., Libman, I. M., Quinn, M., Tamborlane, W. V., Woerner, S. E., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1959 · Cited by 415
El-Khatib, F. H., Balliro, C., Hillard, M. A., Magyar, K. L., Ekhlaspour, L., Sinha, M., Mondesir, D., Esmaeili, A., Hartigan, C., Thompson, M. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32567-3 · Cited by 254
Choudhary, P., Rickels, M. R., Senior, P. A., Vantyghem, M.-C., Maffi, P., Kay, T. W., Keymeulen, B., Inagaki, N., Saudek, F., Lehmann, R., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0090 · Cited by 233 · cited 1×
“As advantageous as this design was for creating similar baseline conditions, this setup is different from the usual clinical causes of severe hypoglycemia, whichmost often comprise of insulin dosing errors, exercise, and alcohol consumption (30).”
BackgroundHaidar, A., Legault, L., Messier, V., Mitre, T. M., Leroux, C., & Rabasa-Lhoret, R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70226-8 · Cited by 214 · cited 1×
“tems have been demonstrated in adults, adolescents, and children (20,21).”
BackgroundTreatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
Kedia (2011) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s20633 · Cited by 131
Haidar, A., Legault, L., Matteau‐Pelletier, L., Messier, V., Dallaire, M., Ladouceur, M., & RABASA-LHORET, R. P. R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00141-2 · Cited by 129 · cited 1×
“tems have been demonstrated in adults, adolescents, and children (20,21).”
BackgroundRickels, M. R., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Sherr, J. L., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Wadwa, R. P., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1498 · Cited by 128
Mini-Dose Glucagon Rescue for Hypoglycemia in Children With Type 1 Diabetes
Haymond, M. W., & Schreiner, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.643 · Cited by 114 · cited 2×
“cemia rescue therapy, glucagondoses in the artificial pancreas setting are much smaller and have been reported to be effective in themanagement of mild or expected forthcoming hypoglycemia in a range of 20–150 mg in children and adolescents with type 1 diabetes (22,23).”
Background
Cited by
Items 101–116 of 116
Neue Entwicklungen bei Diabetes mellitus Typ 1
Haberbosch, L., & Spranger, J. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1240-9714
“[6] Hovelmann U, Bysted BV, Mouritzen U et al.”
BackgroundGlucagon in treatment of hypoglycemia - novelties
Brož, J., Malinovská, J., Brunerová, L., & Urbanová, J. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.022 · Cited by 1
Evolución de los sistemas de infusión de insulina: el camino al páncreas artificial
de la Maza-Viadero, M. E. S., Almeda-Valdés, P., & Faradji-Hazan, R. N. (2021) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m21000015 · Cited by 1
農協におけるBCP(事業継続計画)の策定と実践(第8回)JAらしいBCPの実践とは
Tooru, K. (2013) · 農業協同組合経営実務
Dasiglucagon for treating severe hypoglycemia in patients with diabetes
Ju, Y., Zhang, D., & Yang, J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2103537
“Similar to the native glucagon, dasiglucagon is mainly degraded in blood, liver, and kidney through proteolytic pathway [11,26].”
BackgroundBiological products in medicine
Daniali, M., Mousavi, T., & Abdollahi, M. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00039-7
Furió-Novejarque, C. (2024) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/202872
Glucose Dysregulation Associated with Hypoglycaemia in Childhood and Adolescence
Güemes, M., & Shah, P. (2024) · Endocrinology · doi:10.1007/978-3-030-18901-3_11-1
Glucose Dysregulation Associated with Hypoglycemia in Childhood and Adolescence
Güemes, M., & Shah, P. (2024) · Endocrinology · doi:10.1007/978-3-030-23709-7_11
Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies
Sridharan, K., & Sivaramakrishnan, G. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01988-y · Cited by 2
“Dasiglu-cagon, composed of 29 amino acids with seven amino acid substitutions compared with endogenous glucagon, had better physical and chemical stability in aqueous media due to which the need for reconstitution is eliminated and is immediately available as rescue therapy [67].”
Thota, K., Mogilicharla, A., Sekar, V., & Joguparthi, V. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104305
Kadu, P., Webber, B., DeWolf, E. L., Liu, D., & Webber, M. J. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.178864
Strukova, E. I., & Витольдович, П. К. (2026) · Ural Symposium on Biomedical Engineering, Radioelectronics and Information Technology (USBEREIT) · doi:10.1109/usbereit70063.2026.11581198
“Hoevelmann et al. [10] showed that dasiglucagon, following subcutaneous administration, reaches peak plasma concentration at 35 minutes, its half-life is approximately 30 minutes, and the change in concentration over time follows a predictable pattern.”
A Human Glucoregulatory Model for the Rational Design and Evaluation of Diabetes Therapeutics
Machado, M., Yang, S., Alizadehmojarad, A. A., & Strano, M. S. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00356
Evidence Based Safety of Clinical Use of Dasiglucagon – A Comprehensive Review
Mohamed Saleem, T. S. (2026) · Journal of chemical health risks
Charge density effect of micelles on liquid–liquid phase separation
Farshad, M., Baksi, A., & Whitmer, J. K. (2026) · Soft Matter · doi:10.1039/d6sm00103c
Metadata
- Authors
- Hövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T.
- Affiliations
- Profil Institute for Metabolic Research (DE)
- Zealand Pharma (Denmark) (DK)
- Corresponding author
- Hövelmann, Ulrike
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-22
- Volume
- 41
- Issue
- 3
- Pages
- 531-537
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2781395153
- Cited by
- 115
- References
- 26
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 7 · 2023: 17 · 2022: 18 · 2021: 26 · 2020: 7 · 2019: 15 · 2018: 6
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- dasiglucagon, glucagon analog, severe hypoglycemia, type 1 diabetes, insulin-induced hypoglycemia, pharmacokinetics, pharmacodynamics, subcutaneous injection, salvage therapy, glycemic response, nausea, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glucagon, Half-Life, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.